论文部分内容阅读
华海药业(600521)普利类药物产能全球第一。近两年受非规范市场沙坦类药物增长,加上国内小厂竞争,普利类产品价格下降明显,拖累了公司业绩表现。从去年4季度以来,受欧盟新标准和其他国内厂商退出影响,普利类产品报价保持平稳。预计未来公司更多采取出口制剂,持续降低成本,普利类产品有望平稳增长。
Huahai Pharmaceutical (600,521) Puli class drug production capacity in the world. In the recent two years, due to the growth of sartan in non-standard market, coupled with the competition from small factories in China, the price of Puli products dropped significantly, dragging down the company’s performance. Since the fourth quarter of last year, due to the new EU standards and the withdrawal of other domestic manufacturers, Puli products offer remained stable. It is expected that in the future, the Company will take more export preparations and continue to reduce costs. Puli products are expected to grow steadily.